Table 4 Discontinuation rates of ibrutinib in “real-world practice” studies
1st author | Median duration of treatment (months) | Discontinuation rate | Reason for dose discontinuation | Dose reduction over 1 year (%) | ||||
|---|---|---|---|---|---|---|---|---|
Non-relapse disease | Relapsed disease | |||||||
Toxicity/AE | Death not secondary to CLL/AE | Patient preference/other | CLL progression | CLL transformation | ||||
Ysebaert et al. [10] (French cohort) | 3 (1–10) | 14.5 | 37 | 35 | 13 | 15 | NR | |
Winqvist et al. [11] (Swedish cohort) | 27 (0.6–38) | 24 | 43 | NR | 14 | 43 | 22 | |
Akhtar et al. [16] | 21.9 | 40 | 25 | NR | 22 | 32 | 21 | 31.3 |
Mato et al. [9] | 13.8 (1–76) | 24 | 60 | 3.2 | 14.8 | 12.8 | 9.6 | 17.4 |
Finnes et al. [14] | 13 | 20.3 | 58 | NR | NR | 25 | 16.7 | 21.2 |
UK CLL forum [7] | 16 | 26.3 | 55 | 3.6 | 7.2 | 16.9 | 16.9 | 26 |
Mato et al. [9] | 17 (1–60) | 24, 43 | 63.1, 50.2 | 5.3, 12.1 | 10.5, 6.7 | 15.8, 20.9 | 5.3, 4.6 | 15, 20 |
Iskierka-Jażdżewska et al. [17] (Polish Cohort) | 9.5 (0.1–22.2) | 19.4 | 9.7 | NR | 2.4 | 7.3 | NR | |
Mato et al. [15] | 5 (0.25–41) | 100 | 51 | NR | 13 | 28 | 8 | 11 |